EP1537106A1 - Composes de dihydropyrazolopyridine - Google Patents

Composes de dihydropyrazolopyridine

Info

Publication number
EP1537106A1
EP1537106A1 EP03784497A EP03784497A EP1537106A1 EP 1537106 A1 EP1537106 A1 EP 1537106A1 EP 03784497 A EP03784497 A EP 03784497A EP 03784497 A EP03784497 A EP 03784497A EP 1537106 A1 EP1537106 A1 EP 1537106A1
Authority
EP
European Patent Office
Prior art keywords
cyano
dihydro
pyridine
pyrazolo
substituent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03784497A
Other languages
German (de)
English (en)
Inventor
Toshiyuki c/o MITSUBISHI PHARMA CORP. KOHARA
Kenji c/o MITSUBISHI PHARMA CORP. FUKUNAGA
Tokushi c/o MITSUBISHI PHARMA CORP. HANANO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Pharma Corp
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of EP1537106A1 publication Critical patent/EP1537106A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to new compounds for medicaments, which have a glycogen synthase kinase-3 beta
  • glycogen synthase kinase-3 beta (GSK-3 ⁇ ) , a protein kinase, is involved in the causes of various diseases as noted in the following.
  • Type-II diabetes is a disease in which the insulin reactivity of pancreatic ⁇ cells becomes low and glucose in blood increases. As a result, complications such as diabetic nephropathy, retinosis, heart disease and the like are induced.
  • GSK-3 ⁇ acts for inhibiting glycogen accumulation in peripheral tissues, lowering insulin response and increasing glucose in blood by phosphorylating glycogen synthase. Lithium having a GSK-3 ⁇ -inhibitory activity actually lowers glucose in blood by a GSK-3 ⁇ - inhibitory activity (Proc. Nat. Acad. Sci., 93, 8455
  • medicaments having a GSK-3 ⁇ -inhibitory activity are considered to be a pharmaceutical agent effective for the improvement of Type II diabetes and complications thereof.
  • the developmental mechanism of Alzheimer's dementia has not yet been elucidated. However, it is considered that amyloid aggregation and neurofibril changes are closely related to the cause of the development.
  • GSK-3 ⁇ is involved in both the amyloid aggregation and the neurofibril changes as follows. (1) It binds with variant presenilin and increase production of insoluble amyloid (Proc. Nat. Acad. Sci., 95, 9637 (1998)).
  • Tat which is a protein produced by HIV virus that causes AIDS, enhances GSK-3 ⁇ activity in neurons to induce neuronal death (J. Neuroche ., 73, 578 (1999)).
  • GSK-3 ⁇ inhibitors are considered to be medicaments effective for improving neurodegenerative diseases including Alzheimer's dementia.
  • Lithium and valproic acid which have anti-manic- depressive activity, have a GSK-3 ⁇ inhibitory activity (J. Neurochem., 72, 1327 (1999)).
  • GSK-3 ⁇ inhibitors are considered to be medicaments effective for improving manic-depressive psychosis.
  • NF-AT a transcription factor, is dephosphorylated by calcineurin to increase immunological responses (Science,
  • GSK-3 ⁇ acts for suppressing immunological function by conversely phosphorylating NF-AT.
  • GSK-3 ⁇ inhibitors are considered to be medicaments effective for immunopotentiation.
  • JP-A-3-272189 invention drawn to an improved synthesis method of mevalolacton intermediates
  • JP-A-2-275878 therapeutic agents for hyperlipoproteinemia and atherosclerosis
  • JP-A-1-272584 therapeutic agents for hyperlipoproteinemia
  • JP-A-59-65089, JP-A-59-118786, JP-A-60-56979, JP-A-60-197685 and the like disclose 6- methyl-4-substituted phenyl-4, 7-dihydropyrazolo [3, 4—J] - pyridine-5-carboxylate compounds used for the treatment of cardiovascular diseases, and they are produced by similar methods.
  • the present inventors reproduced the following reaction A according to the method described in JP-A-59- 65089, but failed to obtain the compound of Example 14 (formula (IV) in the following) described therein. They confirmed that only the pyrazolo [1, 5-a] pyrimidine derivative represented by the formula (V) could be produced.
  • the compound of the above formula (IV) can be synthesized according to the method described in J. Chem. Soc, Perkin Trans. 1, 947 (1996), and this publication discloses methyl 4- (2-chlorophenyl) -6-methyl-4, 7-dihydro- lif-pyrazolo [3, 4-b]pyridine-5-carboxylate and the like.
  • An object of the present invention is to provide novel compounds having a selective and strong inhibitory activity against glycogen synthase kinase-3 beta (GSK-3 ⁇ ) , and further, medicaments comprising them and pharmaceutical compositions comprising them.
  • GSK-3 ⁇ glycogen synthase kinase-3 beta
  • the present inventors have intensively studied to achieve the above object, and have found that 4,7- dihydropyrazolo [3, 4-i)] pyridine derivatives have a selective and strong inhibitory activity on GSK-3 ⁇ , which resulted in the completion of the present invention. That is, the present invention relates to medicaments comprising, as an active ingredient, dihydropyrazolopyridine compounds represented by the following formula (I) , which have a GSK-
  • 3 ⁇ -inhibitory activity and can be used as medicaments, optical isomers thereof, pharmaceutically acceptable salts thereof, or hydrates thereof.
  • the present invention provides the following.
  • R° is hydrogen, alkyl, aralkyl, acyl, cycloalkyl, for yl, haloalkyl, aminoalkyl, alkoxyalkyl, phenoxyalkyl, hydroxyalkyl, aminocarbonyl, alkylthiocarbonyl, carboxyalkyl, cycloalkoxyalkyl, alkylsulfinyl, alkylsulfonyl, phenylsulfonyl, phenylsulfinyl, mercaptoalkyl, alkylthioalkyl, acyloxyacetyl, acyloxyalkyl, phenyl optionally having substituent (s) , aromatic heterocyclic group optionally having substituent (s) , phenylalkyl optionally having substituent (s) , or a group of the formula: -COOR 8 (wherein R 8 is hydrogen, alkyl, aryl optionally having substituen (s) or a
  • aromatic heterocyclic group (5) a group derived from a benzene ring fused with a saturated or unsaturated 5 or 6 membered carbocyclic ring,
  • R 6 and R 7 are each phenyl optionally having substituent (s) or an aromatic heterocyclic group, or R 2 and R 3 in conjunction form a ring optionally containing heteroatom(s) , wherein the ring may be fused with a benzene ring optionally having substituent (s) ;
  • R 4 is alkoxycarbonyl, alkylcarbonyl, alkylsulfonyl, alkylsulfinyl, phenylsulfinyl, phenylsulfonyl, dialkylphosphinyl, dialkylphosphonyl, phenyl optionally having substituent (s) , an aromatic heterocyclic group optionally having substituent (s) , cyano or nitro; and R 5 is alkyl, phenylaminoalkyl, acyl, acylalkyl, aminocarbonyl, arylaminocarbonyl, a saturated or unsaturated 4 to 7 membered heterocyclic ring optionally having substituent (s) a saturated 3 to 7 membered carbocyclic ring having substituent (s) , alkyl substituted by a saturated or unsaturated 4 to 7 membered ring containing 1 or 2 nitrogen atom(s), which optionally has a substituent, or a group of the formula:
  • R 4 is alkoxycarbonyl, alkylcarbonyl, alkylsulfonyl, alkylsulfinyl, phenylsulfinyl, phenylsulfonyl, dialkylphosphinyl, dialkylphosphonyl, phenyl optionally having substituent (s) , an aromatic heterocyclic group having substituent (s) , cyano or nitro
  • R 5 is alkyl, phenyla inoalkyl, acyl, acylalkyl, aminocarbonyl, aryla inocarbonyl, a saturated or unsaturated 4 to 7 membered heterocyclic ring optionally having substituent (s) , a saturated 3 to 7 membered carbocyclic ring having substituent (s) , alkyl substituted by a saturated or unsaturated 4 to 7 membered ring containing 1
  • a medicament comprising a dihydropyrazolopyridine compound of the above-described [1] or [2], an optically active form thereof, or a pharmaceutically acceptable salt thereof.
  • a pharmaceutical composition comprising a dihydropyrazolopyridine compound of the above-described [1] or [2], an optically active form thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive.
  • a glycogen synthase kinase-3 beta inhibitor comprising a compound selected from the group consisting of a dihydropyrazolopyridine compound of the above-described [1], an optically active form thereof and a pharmaceutically acceptable salt thereof.
  • the disease is selected from the group consisting of Alzheimer's disease, ischemic cerebrovascular disorders, Down's syndrome, cerebral ischemia due to cerebral amyloid angiopathy, progressive supranuclear paralysis, subacute sclerosing panencephalitic Parkinsonism, postencephalitic Parkinsonism, boxer's encephalopathy, Parkinsonism dementia complex of Gu
  • the formula (I) indicates the presence of tautomers represented by the following formulas (I-a) and (I-b), based on the positions of hydrogen atoms of the pyrazole ring.
  • the present invention encompasses each isomer of formulas (I-a) and (I-b), and a mixture of these isomers.
  • Alkyl means a linear or branched hydrocarbon chain of 1 to 8 carbon atom(s), and includes methyl, ethyl, propyl, butyl, pentyl (i.e., a yl) , hexyl, or a structural isomer thereof, such as isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, tert-pentyl and the like, with a preference for alkyl having 1 to 4 carbon atom(s).
  • the alkyl of R 2 is preferably alkyl having 1 to 4 carbon atoms.
  • the alkyl of R 5 is preferably alkyl having 2 to 8 carbon atoms.
  • the "alkyl having 2 to 8 carbon atoms" concretely includes ethyl, propyl, butyl, pentyl (i.e., amyl) , hexyl, heptyl and octyl, or a structural isomer thereof, such as isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, tert-pentyl and the like.
  • Alkyl having 2 to 4 carbon atoms is more preferable, and propyl is particularly preferable.
  • "Acyl” means C 2 -C ⁇ acyl, and includes “alkylcarbonyl” having 2 to 8 carbon atoms, such as acetyl, propionyl, butyryl, isobutyryl, valeryl, pivaloyl, hexanoyl, heptanoyl and the like, at R 4 preferably having 2 to 5 carbon atoms, "C 7 _Ci 2 arylcarbonyl” such as benzoyl, naphthoyl and the like, and "C-Ci2 aralkylcarbonyl” such as benzylcarbonyl, 2-phenylethylcarbonyl, 3-phenylpropylcarbonyl and the like, and the like.
  • the benzene and naphthalene rings may have 1 to 5 substituent (s) and substitution sites are not particularly limited.
  • “Acylalkyl” is acylalkyl consisting of the above Ci- C 8 alkyl and the above C2-C 1 4 acyl, and includes, for example, acetylmethyl, propionylmethyl, butyrylmethyl, isobutyryl ethyl, valerylmethyl, pivaloylmethyl, 2- acetylethyl, 2-propionylethyl, 3-acetylpropyl and the like.
  • “Cycloalkyl” means a cyclic hydrocarbon chain of 3 to 8 carbon atoms.
  • Cycloalkyl concretely includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like, with a preference for cycloalkyl having 3 to 6 carbon atoms.
  • the cycloalkyl may have 1 to 5 substituent (s) and substitution sites are not particularly limited.
  • Halogen represents fluorine, chlorine, bromine or iodine .
  • Amino is primary amino, secondary or tertiary amino having the above C ⁇ -C 8 alkyl, and includes, for example, amino, mono- or di-C ⁇ -C 8 alkyl-substituted amino such as methylamino, dimethylamino, ethyla ino, diethylamino, propylamino, dipropylamino, butyla ino, dibutylamino and the like.
  • Alkylthio is a linear or branched alkylthio having 1 to 6 carbon atom(s), and includes, for example, methylthio, ethylthio, propylthio, butylthio, pentylthio (i.e., amylthio) , hexylthio and structural isomers thereof, such as isopropylthio, isobutylthio, sec-butylthio, tert- butylthio, isopentylthio, neopentylthio, tert-pentylthio and the like, with a preference for alkylthio having 1 to 3 carbon atom(s) .
  • Phenylthio means phenylthio optionally having 1 to 5 substituent (s) on the phenyl and substitution sites are not particularly limited.
  • Haloalkyl is the above C ⁇ -C 8 alkyl substituted by 1 to 5 halogen (s), and represents fluoromethyl, chloromethyl, difluoro ethyl, trifluoromethyl, 2, 2, 2-trifluoroethyl, 2, 2, 3, 3, 3-pentafluoropropyl and the like.
  • Aminoalkyl is C ⁇ -C 8 alkyl having primary amino, and includes, for example, aminomethyl, 2-aminoethyl, 3- aminopropyl, 4-aminobutyl and the like, with a preference for aminoalkyl containing alkyl having 1 to 4 carbon atom(s) .
  • Acylamino is acylamino having the above C 2 -C 14 acyl, and represents, for example, acetylamino, propionyla ino, butyrylamino, valerylamino, pivaloylamino, benzoylamino, phenylacetyla ino, phenylpropionylamino, phenylbutyrylamino and the like.
  • Alkoxy is alkoxy having the above C ⁇ -C 8 alkyl, and includes, for example, methoxy, ethoxy, propoxy, butoxy, pentyloxy (i.e., amyloxy) , hexyloxy and structural isomers thereof, such as isopropoxy, isobutoxy, sec-butoxy, tert- butoxy, isopentyloxy, neopentyloxy, tert-pentyloxy and the like, with a preference for alkoxy having 1 to 4 carbon atom(s) .
  • Cycloalkoxy is cycloalkoxy having the above C ⁇ C 8 cycloalkyl, and includes, for example, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy and the like, with a preference for cycloalkoxy having cycloalkyl having 3 to 6 carbon atoms .
  • Phenoxy means phenyloxy optionally having 1 to 5 substituent (s) on the phenyl and substitution sites are not particularly limited.
  • Phenylalkoxy is phenylalkoxy having the above C ⁇ -C 8 alkoxy, and includes, for example, benzyloxy, 1- phenylethoxy, 2-phenylethoxy, 3-phenylpropoxy, 4- phenylbutoxy, 1-methyl-l-phenylethoxy, l-methyl-2- phenylethoxy, 1-phenylpropoxy, 2-pheylpropoxy, 1-methyl-l- phenylpropoxy, l-methyl-2-phenylpropoxy, l-methyl-3- phenylpropoxy and the like, with a preference for phenylalkoxy containing alkoxy having 1 to 4 carbon atom(s) .
  • the phenylalkoxy optionally has 1 to 5 substituent (s) on the phenyl and substitution sites are not particularly limited.
  • aminoalkoxy is aminoalkoxy consisting of the above amino and C ⁇ -C 8 alkoxy, and includes, for example, aminomethoxy, methylaminomethoxy, dimethylaminomethoxy, 2- (dimethylamino) ethoxy, 3- (dimethylamino)propoxy, 4- (dimethylamino) butoxy and the like, with a preference for aminoalkoxy consisting of tertiary amino containing alkyl having 1 to 4 carbon atom(s) , and alkoxy having 1 to 4 carbon atom(s) .
  • Alkoxyalkyl is alkoxyalkyl consisting of the above Ci-Cs alkoxy and C ⁇ -C 8 alkyl, and includes, for example, methoxymethyl, ethoxymethyl, 2-methoxyethyl, propoxymethyl, isopropoxymethyl and the like, with a preference for alkoxyalkyl consisting of alkoxy having 1 to 4 carbon atom(s) and alkyl having 1 to 4 carbon atom(s) .
  • Phenoxyalkyl is phenoxyalkyl consisting of the above phenoxy and C ⁇ -C 8 alkyl, and includes, for example, phenoxymethyl, 2-phenoxyethyl, 3-phenoxypropyl and the like, with a preference for phenoxyalkyl containing alkyl having 1 to 4 carbon atom(s) .
  • the phenoxyalkyl optionally has 1 to 5 substituent (s) on the phenyl and substitution sites are not particularly limited.
  • Hydroalkyl is hydroxyalkyl having the above C ⁇ -C 8 alkyl, and includes, for example, hydroxymethyl, 2- hydroxyethyl, 3-hydroxypropyl and the like, with a preference for hydroxyalkyl containing alkyl having 1 to 4 carbon atom(s) .
  • Alkoxycarbonyl is alkoxycarbonyl having the above C ⁇ -C 8 alkoxy, and includes, for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl and structural isomers thereof, such as isopropoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl, isopentyloxycarbonyl, neopentyloxycarbonyl, tert- pentyloxycarbonyl and the like, with a preference for alkoxycarbonyl, in which the alkoxy moiety has 1 to 4 carbon atom(s) .
  • the alkoxycarbonyl of R 4 is preferably alkoxycarbonyl having 2 to 5 carbon atoms.
  • "Phenoxycarbonyl” is phenoxycarbonyl optionally having 1 to 5 substituent (s) on the phenyl and substitution sites are not particularly limited.
  • Aminocarbonyl is aminocarbonyl having the above amino including mono- or di-C ⁇ -C 8 alkyl-substituted amino, and includes, for example, aminocarbonyl (i.e., carbamoyi), methylaminocarbonyl, dimethylaminocarbonyl, ethylaminocarbonyl, diethylaminocarbonyl, propyla inocarbonyl, dipropylaminocarbonyl and the like.
  • aminocarbonyl i.e., carbamoyi
  • methylaminocarbonyl dimethylaminocarbonyl
  • ethylaminocarbonyl ethylaminocarbonyl
  • diethylaminocarbonyl diethylaminocarbonyl
  • propyla inocarbonyl dipropylaminocarbonyl and the like.
  • Alkylthiocarbonyl is alkylthiocarbonyl having the above C ⁇ -C 6 alkylthio, and includes, for example, methylthiocarbonyl, ethylthiocarbonyl, propylthiocarbonyl, butylthiocarbonyl and structural isomers thereof, such as isopropylthiocarbonyl, isobutylthiocarbonyl, sec- butylthiocarbonyl, tert-butylthiocarbonyl and the like, with a preference for alkylthiocarbonyl, in which the alkyl moiety has 1 to 3 carbon atoms.
  • Carboxyalkyl is carboxyalkyl having the above C ⁇ -C 8 alkyl, and includes, for example, carboxymethyl, carboxyethyl, carboxypropyl and the like, with a preference for carboxyalkyl containing alkyl having 1 to 4 carbon atom(s) .
  • Cycloalkoxyalkyl is cycloalkoxyalkyl consisting of the above C 3 -C 8 cycloalkoxy and C ⁇ --C 8 alkyl, and includes, for example, cyclopropoxymethyl, cyclopropoxyethyl, cyclobutoxy ethyl, cyclopentyloxymethyl, cyclohexyloxymethyl and the like, with a preference for cycloalkoxyalkyl consisting of cycloalkoxy having 3 to 6 carbon atoms and alkyl having 1 to 4 carbon atom(s) .
  • the cycloalkoxyalkyl optionally has 1 to 3 substituent (s) on the cycloalkyl and substitution sites are not particularly limited.
  • Alkylsulfinyl is alkylsulfinyl having the above Ci- C 8 alkyl, and includes, for example, methylsulfinyl, ethylsulfinyl, propylsulfinyl, isopropylsulfinyl and the like, with a preference for alkylsulfinyl containing alkyl having 1 to 5 carbon atom(s) .
  • the alkylsulfinyl of R 4 is preferably alkylsulfinyl having 1 to 4 carbon atoms.
  • Phenylsulfinyl means phenylsulfinyl optionally having 1 to 5 substituent (s) on the phenyl and substitution sites are not particularly limited.
  • Alkylsulfonyl is alkylsulfonyl having the above C ⁇ C 8 alkyl, and includes, for example, methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl and the like, with a preference for alkylsulfonyl containing alkyl having 1 to 5 carbon atom(s) .
  • the alkylsulfonyl of R 4 is preferably alkylsulfonyl having 1 to 4 carbon atoms.
  • Phenylsulfonyl means phenylsulfonyl optionally having 1 to 5 substituent (s) on the phenyl and substitution sites are not particularly limited.
  • Mercaptoalkyl is mercaptoalkyl having the above C ⁇
  • C 8 alkyl includes, for example, mercaptomethyl, mercaptoethyl, mercaptopropyl and the like, with a preference for mercaptoalkyl containing alkyl having 1 to 4 carbon atom(s).
  • Alkylthioalkyl is alkylthioalkyl consisting of the above C ⁇ -C 3 alkylthio and C ⁇ -C 8 alkyl, and includes, for example, methylthiomethyl, methylthioethyl, methylthiopropyl, ethylthiomethyl, ethylthioethyl, ethylthiopropyl and the like, with a preference for alkylthioalkyl consisting of alkylthio having 1 to 3 carbon atom(s) and alkyl having 1 to 4 carbon atom(s) .
  • Aryl is aryl having 6 to 14 carbon atoms, and includes, for example, phenyl, 1-naphthyl, 2-naphthyl, 1- anthryl, 2-anthryl and the like. They may have 1 to 5 substituent (s) and substitution sites are not particularly limited.
  • “Aralkyl” is aralkyl wherein the above C ⁇ -C 8 alkyl is substituted by the above C 6 -C 14 aryl, and includes benzyl, 2-phenylethyl, 3-phenylpropyl, 1-naphthylmethyl, 2- naphthylmethyl and the like. These may have 1 to 5 substituent (s) on the aryl moiety and substitution sites are not particularly limited.
  • Acyloxyacetyl is acyloxyacetyl having the above C 2 - C 14 acyl, and includes, for example, acetyloxyacetyl, propionyloxyacetyl, butyryloxyacetyl, benzoyloxyacetyl and the like.
  • Acyloxyalkyl is acyloxyalkyl having the above C 2 -C ⁇ 4 acyl and C ⁇ -C 8 alkyl, and includes, for example, acetyloxymethyl, propionyloxymethyl, butyryloxymethyl, benzoyloxymethyl, 2-acetyloxyethyl, 2-propionyloxyethyl, 2- butyryloxyethyl, 2-benzoyloxyethyl and the like.
  • substituent of the "phenyl optionally having substituent (s) " is exemplified by those mentioned for the "substituent” below, wherein the number of the substituent is generally 1 to 5, preferably 1 to 3. Phenyl having 1 or 2 substituent (s) is particularly preferable and substitution sites are not particularly limited.
  • Aromatic heterocyclic group is, for example, a 5- or 6-membered aromatic heterocyclic group containing 1 to 3 heteroatom(s) selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom, and includes, for example, thiophenyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, ,isoxazolyl, pyridyl, pyridazinyl, pyrimidyl, pyrazinyl, oxadiazolyl (e.g., 1, 3, 4-oxadiazolyl, 1, 2, 4-oxadiazolyl, etc.), and the like.
  • the aromatic heterocyclic group may have 1 to 6 substituent (s) and substitution sites are not particularly limited.
  • R 9 is each independently hydrogen, alkyl, acyl, aralkyl, cycloalkyl, formyl, haloalkyl, a inoalkyl, phenylalkyl, alkoxyalkyl, phenoxyalkyl, guanyl, hydroxyalkyl, aminocarbonyl, alkylthiocarbonyl, carboxyalkyl, alkoxycarbonyl, phenoxycarbonyl, alkylsulfinyl, alkylsulfonyl, phenylsulfonyl, mercaptoalkyl, alkylthioalkyl, acyloxyacetyl, acyloxyalkyl, aryl optionally having substituent (s) , aromatic heterocyclic group optionally having substituent (s) , or phenylalkyl optionally having substituent (s) .
  • R 10 is alkyl, acyl, aralkyl, cycloalkyl, formyl, haloalkyl, aminoalkyl, alkoxyalkyl, phenylalkyl, phenoxyalkyl, amino, hydroxyalkyl, aminocarbonyl, alkylthiocarbonyl, carboxyalkyl, alkylsulfinyl, alkylsulfonyl, phenylsulfonyl, mercaptoalkyl, alkylthioalkyl, acyloxyacetyl, acyloxyalkyl, aryl optionally having substituent (s) , aromatic heterocyclic group optionally having substituent (s) , or phenylalkyl optionally having substituent (s) , and R 10 ' is hydrogen, alkyl, acyl, aralkyl, cycloalkyl, formyl, haloalkyl, aminoalkyl, alkoxyalkyl,
  • Phenylalkyl is phenylalkyl consisting of phenyl and the above Cx-Cs alkyl, and includes, for example, benzyl, 2-phenylethyl, 3-phenylpropyl, 4-phenylbutyl, 1-phenylethyl, l-methyl-2-phenylethyl, 1-phenylpropyl, 2-phenylpropyl, 1- methyl-1-phenylpropyl, l-methyl-2-phenylpropyl, l-methyl-3- phenylpropyl and the like, with a preference for phenylalkyl consisting of phenyl and alkyl having 1 to 4 carbon atom(s) .
  • phenylalkyl optionally having substituent (s) are the same as those for the above-mentioned “aromatic heterocyclic group” and substitution sites are not particularly limited.
  • Dialkylphosphinyl is dialkylphosphinyl having the above C ⁇ -C 8 alkyl, and includes, for example, dimethylphosphinyl, diethylphosphinyl, dipropylphosphinyl and the like, with a preference for dialkylphosphinyl containing alkyl having 1 to 4 carbon atom(s).
  • Dialkylphosphonyl is dialkylphosphonyl having the above Q L -C 8 alkyl, and includes, for example, dimethylphosphonyl, diethylphosphonyl, dipropylphosphonyl and the like, with a preference for dialkylphosphonyl containing alkyl having 1 to 4 carbon atom(s).
  • substituted includes alkyl, acyl, cycloalkyl, phenyl, aromatic heterocyclic group, phenylalkyl, hydroxy, carboxy, thiol, halogen, amino, formyl, carbamoyi, cyano, nitro, alkylthio, haloalkyl, aminoalkyl, acylamino, alkoxy, cycloalkoxy, phenoxy, phenylalkoxy, aminoalkoxy, alkoxyalkyl, phenoxyalkyl, hydroxyalkyl, alkoxycarbonyl, alkylsulfinyl, aminocarbonyl, alkylthiocarbonyl and the like.
  • Ring optionally containing heteroatom (s) is a 5 or 6 membered carbocyclic ring optionally containing 1 to 3 heteroatom(s) selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom, with particular preference given to a ring containing sulfur atom.
  • the ring may be substituted by one or more of the above substituents or oxo groups.
  • the substitution site is not particularly limited.
  • This ring is formed by R 2 and R3 in the formula (I) together with the attached carbon atom. By forming this ring, a spiro ring is formed in the compound of the formula (I) .
  • the above ring can be fused with a benzene ring optionally having substituent (s) and substitution sites are not particularly limited.
  • Such a ring includes, for example, 2, 3-dihydrobenzo [b] thiophene, 2, 3-dihydrobenzo [jb] thiophen-1-oxide and the like.
  • a group derived from a benzene ring fused with a saturated or unsaturated 5 or 6 membered carbocyclic ring' represents a group derived from naphthalene, 1,2- dihydronaphthalene, 1, 2, 3, 4-tetrahydronaphthalene, indan and the like. Of these, naphthyl such as naphthalen-1-yl and the like, and indanyl such as indan-4-yl and the like are preferable.
  • the group may have 1 to 4 substituent (s) and substitution sites are not particularly limited.
  • a group derived from a benzene ring fused with a saturated or unsaturated 5 to 7 membered carbocyclic ring containing 1 to 3 heteroatom (s) includes the following groups and the like.
  • 2, 1, 3-benzoxadiazole, dihydrobenzo [b] furan, methylenedioxyphenyl and 3, 4-dihydro-2H-benzopyrane are preferable, and 2, 1, 3-benzoxadiazol-4-yl, 2, 3-dihydrobenzo- [j] furan-7-yl, 2, 3- (methylenedioxy) phenyl and 3,4-dihydro- 2H-benzopyran-8-yl are particularly preferable.
  • the group may have 1 to 3 substituent (s) and substitution sites are not particularly limited.
  • a group derived from a 5 to 7 membered saturated or unsaturated carbocyclic ring containing 1 to 3 heteroato (s) , which is fused with a benzene ring includes the following groups and the like.
  • the group may have 1 to 5 substituent (s) and substitution sites are not particularly limited.
  • Alkylcarbonylalkyl is, for example, C1-C4 alkyl- carbonyl-C ⁇ -C alkyl, and includes, for example, methylcarbonylmethyl, ethylcarbonylmethyl, propylcarbonylmethyl, butylcarbonylmethyl and the like.
  • Arylaminocarbonyl is C 6 -C ⁇ o aryl-aminocarbonyl, and includes, for example, phenylaminocarbonyl, naphthylaminocarbonyl and the like.
  • the arylaminocarbonyl optionally has 1 to 3 substituent (s) on the aryl and substitution sites are not particularly limited.
  • Alkylaminocarbonyl is C-C ⁇ 4 aralkyl-aminocarbonyl, and includes, for example, benzylaminocarbonyl and the like.
  • the aralkylaminocarbonyl optionally has 1 to 3 substituent (s) on the aryl and substitution sites are not particularly limited.
  • Alkyl substituted by a saturated or unsaturated 4 to 7 membered ring containing 1 or 2 nitrogen atom(s), which optionally has a substituent means C ⁇ C 8 alkyl substituted by "a saturated or unsaturated 4 to 7 membered ring containing 1 or 2 nitrogen atom(s)", such as pyrrole, pyrroline, pyrazole, pyridine, piperidine, piperazine, homopiperadine or morpholine and the like, which optionally has a substituent such as C 1 -C4 alkyl, C6-C 10 aryl such as phenyl, naphthyl and the like, and includes, for example, (4-phenylpiperazin-l-yl) methyl, 2- (4-phenylpiperazin-l- yl) ethyl, 3- (4-phenylpiperazin-l-yl) propyl, (4- (naphthalen-1-yl) piperazin-1-yl) methyl, 2-
  • Phenyla inoalkyl is phenylamino-C ⁇ -C alkyl, and includes, for example, phenylaminomethyl, 2- phenylaminoethyl, 3-phenylaminopropyl, 4-phenylaminobutyl and the like.
  • the phenylaminoalkyl optionally has 1 to 3 substituent (s) on the phenyl and substitution sites are not particularly limited.
  • Phenylalkylcarbonyl is phenyl-C ⁇ -C 4 alkyl-carbonyl, and includes, for example, benzylcarbonyl, 2- phenylethylcarbonyl, 3-phenylpropylcarbonyl, 4- phenylbutylcarbonyl and the like.
  • the phenylalkylcarbonyl optionally has 1 to 3 substituent (s) on the phenyl and substitution sites are not particularly limited.
  • “Alkyl” in the R 11 is C 1 -C4 alkyl, and includes, for examples, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl and the like.
  • Alkylsulfonyl in the R u is C 1 -C 4 alkyl-sulfonyl, and includes, for example, methylsulfonyl, ethylsulfonyl, propylsulfonyl and the like.
  • Phenylsulfonyl in the R 11 is phenylsulfonyl optionally having 1 to 3 substituent (s) on the phenyl and substitution sites are not particularly limited.
  • Phenylalkylsulfonyl in the R 11 is phenyl-C ⁇ -C 4 alkyl- sulfonyl, and includes, for example, benzylsulfonyl, 2- phenylethylsulfonyl, 3-phenylpropylsulfonyl, 4- phenylbutylsulfonyl and the like.
  • the phenylalkylsulfonyl optionally has 1 to 3 substituent (s) on the phenyl and substitution sites are not particularly limited.
  • Alkylsulfinyl in the R 11 is C 1 -C 4 alkyl-sulfinyl, and includes, for example, methylsulfinyl, ethylsulfinyl, propylsulfinyl and the like.
  • Phenylsulfinyl in the R 11 is phenylsulfinyl optionally having 1 to 3 substituent (s) on the phenyl and substitution sites are not particularly limited.
  • Phenylalkylsulfinyl in the R u is phenyl-C ⁇ -C4 alkyl- sulfinyl, and includes, for example, benzylsulfinyl, 2- phenylethylsulfinyl, 3-phenylpropylsulfinyl, 4- phenylbutylsulfinyl and the like.
  • the phenylalkylsulfinyl optionally has 1 to 3 substituent (s) on the phenyl and substitution sites are not particularly limited.
  • Alkoxycarbonyl in the R 11 is C ⁇ -C alkoxy-carbonyl, and includes, for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl and the like.
  • Phenylalkoxycarbonyl in the R 11 is phenyl-C ⁇ -C4 alkoxy-carbonyl, and includes, for example, benzyloxycarbonyl, 2-phenylethoxycarbonyl, 3- phenylpropoxycarbonyl, 4-phenylbutoxycarbonyl and the like.
  • the phenylalkoxycarbonyl optionally has 1 to 3 substituent (s) on the phenyl and substitution sites are not particularly limited.
  • Alkylcarbonyl in the R 11 is C 1 -C 4 alkyl-carbonyl and includes, for example, acetyl, propionyl, butylcarbonyl and the like.
  • Phenylcarbonyl in the R 11 is phenylcarbonyl optionally having 1 to 3 substituent (s) on the phenyl and substitution sites are not particularly limited.
  • Phenylalkylcarbonyl in the R 11 is phenyl-C ⁇ -C4 alkylcarbonyl, and includes, for example, benzylcarbonyl, 2- phenylethylcarbonyl, 3-phenylpropylcarbonyl, 4- phenylbutylcarbonyl and the like.
  • the phenylalkylcarbonyl optionally has 1 to 3 substituent (s) on the phenyl and substitution sites are not particularly limited.
  • Phenoxycarbonyl in the R 11 means phenoxycarbonyl optionally having 1 to 3 substituent (s) on the phenyl and substitution sites are not particularly limited.
  • Alkyl in the R 12 is C 1 -C 4 alkyl, and includes, for examples, methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, tert-butyl and the like.
  • the compounds represented by the formula (I) of the present invention can be converted to acid addition salts with pharmaceutically acceptable acids and such acid addition salts are also encompassed in the present invention.
  • acid addition salts include, for example, salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and salts with organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, citric acid, tartaric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, glutamic acid and the like.
  • R 2 , R 3 , R 4 and R 5 are as defined above.
  • Me1drum' s acid of the formula (VI) and a carbonyl derivative of the formula (VII) are reacted with a carbonyl derivative of the formula (VIII) in the presence of ammonium acetate to give an amide derivative of the formula (IX) .
  • the reaction is carried out in the presence of a carboxylic acid solvent inert to the reaction.
  • a carboxylic acid solvent inert to the reaction.
  • the solvent formic acid, acetic acid, propionic acid, butyric acid, valeric acid and the like are generally used.
  • the reaction is carried out at any temperature, for example, from 0°C to 200°C, preferably from 60°C to 100°C.
  • R 2 , R 3 , R 4 and R 5 are as defined above.
  • the obtained amide derivative of the formula (IX) is reacted in the presence of dimethylformamide and phosphorus oxychloride to give a formyl derivative of the formula (X) ,
  • the reaction is carried out in the presence of a solvent inert to the reaction.
  • a solvent inert As the solvent, ether, tetrahydrofuran, dioxane, ethyl acetate, acetonitrile, benzene, toluene, chloroform, dichloromethane, dimethylformamide, dimethyl sulfoxide and the like are generally used.
  • the reaction is carried out at any temperature, for example, from 0°C to 200°C, preferably from 0°C to 60°C.
  • the compound (I) of the present invention can be produced by reacting the obtained formyl derivative of the formula (X) in the presence of hydrazine.
  • the reaction is carried out in the presence of a solvent inert to the reaction.
  • a solvent inert As the solvent, ether, tetrahydrofuran, dioxane, ethyl acetate, acetonitrile, benzene, toluene, chloroform, dichloromethane, dimethylformamide, dimethyl sulfoxide, pyridine, alcohol and the like are generally used.
  • the reaction is carried out at any temperature, for example, from 0°C to 200°C, preferably from 60°C to 100°C.
  • the carbonyl derivative of the formula (VII) which is a starting material, can be synthesized according to the methods described in J. Org. Chem., 46, 783 (1981), Eur. J. Med. Chem., 31, 3 (1996) and Tetrahedron Lett., 24, 5023 (1983) .
  • the carbonyl derivative of the formula (VIII) can be synthesized according to the method described in Synthesis, 290 (1993) .
  • R 1 , R 2 , R 3 , R 4 and R 5 are as defined above.
  • the compounds (I) of the present invention can be produced by reacting a inopyrazole of the formula (XI) and a carbonyl derivative of the formula (VII) with a carbonyl derivative of the formula (VIII) .
  • the reaction is carried out in the presence of a solvent inert to the reaction.
  • a solvent inert As the solvent, ether, tetrahydrofuran, dioxane, ethyl acetate, acetonitrile, benzene, toluene, chloroform, dichloromethane, dimethylformamide, dimethyl sulfoxide, alcohol and the like are generally used.
  • the reaction is carried out at any temperature, for example, from 0°C to 200°C, preferably from 60°C to 100°C.
  • R°, R 1 , R 2 , R 3 , R 4 and R 5 are as defined above, and X represents halogen, provided that R° is not hydrogen.
  • the compounds (I) of the present invention can be produced by reacting a dihydropyrazolopyridine derivative of the formula (XI) with halide of the formula (XII) in the presence of a base.
  • a base includes, for example, triethylamine, diisopropylethylamine, 4- dimethylaminopyridine and the like.
  • the reaction is carried out in the presence of a solvent inert to the reaction.
  • a solvent one without hydroxy group is generally used, such as tetrahydrofuran, ethyl acetate, benzene, toluene, chloroform, dichloromethane, dimethylformamide, dimethylimidazolidinone and the like.
  • the reaction is carried out at any temperature, for example, from -10°C to 200°C, preferably from 0°C to 100°C.
  • the compounds (I) of the present invention can be produced by reacting a dihydropyrazolopyridine derivative of the formula (XI) with anhydride of the formula (XIII) such as acetic anhydride in the presence of a base.
  • a base includes, for example, triethyla ine, pyridine, 4-dimethylaminopyridine and the like.
  • the reaction is carried out in the presence of a solvent inert to the reaction.
  • a solvent one without hydroxy group is generally used, such as tetrahydrofuran, ethyl acetate, benzene, toluene, chloroform, dichloromethane, dimethylformamide, dimethylimidazolidinone, pyridine and the like.
  • the reaction is carried out at any temperature, for example, from -10°C to 200°C, preferably from 0°C to 100°C.
  • the compound (I) of the present invention thus produced can be isolated and purified as a free compound or a salt thereof. Isolation and purification is carried out by a conventional chemical process such as extraction, concentration, evaporation, crystallization, filtration, recrystallization, various kinds of chromatography and the like.
  • a desired optically active compound can be separated by, for example, fractional recrystallization with optically active acid, or passing through a column packed with optically active carrier.
  • the present invention also encompasses optically active compounds.
  • the compounds of the present invention obtained by the above methods have a weak inhibitory activity on kinases other than GSK-3 ⁇ such as CaM kinase II, MAP kinase, Casein kinase, PKA, PKC and ROCK, but have a strong inhibitory activity on GSK-3 ⁇ .
  • the compounds of the present invention have a GSK-3 ⁇ -selective inhibitory activity and can be medicaments with small side-effect for diabetes, diabetic complications, neurodegenerative diseases (Alzheimer's disease, ischemic cerebrovascular disorders, Down's syndrome, cerebral ischemia due to cerebral amyloid angiopathy, progressive supranuclear paralysis, subacute sclerosing panencephalitic Parkinsonism, postencephalitic Parkinsonism, boxer' s encephalopathy, Parkinsonism dementia complex of Guam, Lewy body disease, Pick's disease, corticobasal degeneration, frontotemporal dementia, AIDS encephalopathy, Huntington' s disease, manic- depressive psychosis and the like) , alopecia, breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and several virus-induced tumors.
  • the compounds of the present invention are useful as immunopotentiators .
  • Formulations comprising the compounds of the present invention or salts thereof as an active ingredient are prepared using carriers, excipients and other additives conventionally used for formulation.
  • the carrier and excipient for formulation may be a solid or liquid, and include, for example, lactose, magnesium stearate, starch such as corn starch, talc, gelatin, agar, pectin, gum Arabic, olive oil, sesame oil, cacao butter, ethylene glycol and other conventionally used substances.
  • Administration may be oral administration of tablet, pill, capsule, granule, powder, solution and the like, or parenteral administration by injection (intravenous injection, intramuscular injection and the like), suppository, transdermal agent and the like. While the dose is appropriately determined on each case in consideration of symptom, age and sex of the administration subject, and the like, it is generally 1 - 1,000 mg, preferably 50 - 200 mg per day for an adult person, which is orally administered once to several times a day, or 1 - 500 mg per day for an adult person, which is intravenously administered once to several times a day, or continuously administered intravenously for 1 to 24 hours a day. Examples
  • Example 1 The present invention is described in detail in the following, based on Examples, Formulation Examples and Experimental Examples. The scope of the present invention is not limited to these examples.
  • Example 1 The present invention is described in detail in the following, based on Examples, Formulation Examples and Experimental Examples. The scope of the present invention is not limited to these examples.
  • the title compound was prepared from ethyl nipecotate,
  • the title compound was prepared from ethyl morpholine-2- carboxylate, 2, 1, 3-benzoxadiazole-4-aldehyde and 3-amino- pyrazole in the same manner as in Example 1.
  • the title compound was prepared from benzoylchloride, ethyl isonipecotate, 2, 1, 3-benzoxadiazole-4-aldehyde and 3- aminopyrazole in the same manner as in Example 25. MP:228°C. MS (FAB) :452 (M + +l) .
  • the title compound was prepared from acetyl chloride, ethyl 1, 2, 3, 6-tetrahydropyridine-4-carboxylate, 2,1,3- benzoxadiazole-4-aldehyde and 3-aminopyrazole in the same manner as in Example 25.
  • the title compound was prepared from methanesulfonyl- chloride, ethyl isonipecotate, 2, 1, 3-benzoxadiazole-4- aldehyde and 3-aminopyrazole in the same manner as in Example 25. MP:243°C. MS (El) :425(M + ) .
  • the title compound was prepared from 1-chloro-N, N- dimethylformamide, ethyl isonipecotate, 2, 1, 3-benzoxa- diazole-4-aldehyde and 3-aminopyrazole in the same manner as in Example 25.
  • the title compound was prepared from acetyl chloride, ethyl nipecotate, 2, 1, 3-benzoxadiazole-4-aldehyde and 3- a inopyrazole in the same manner as in Example 25. MP:219°C.
  • the title compound was prepared from ethyl nipecotate,
  • the title compound was prepared from methanesulfonyl chloride, ethyl isonipecotate, 2-bromo-3-cyanobenzaldehyde and 3-aminopyrazole in the same manner as in Example 25. MP:>280°C. MS (El) :487 (M + ) .
  • Example 62 4- (2-Bromo-3-cyanophenyl) -5-cyano-4, 7-dihydro-6- (2- oxocyclohexan-1-yl) -2ff-pyrazolo [3, 4-b]pyridine
  • the title compound was prepared from ethyl 2- cyclohexanonecarboxylate, 2-bromo-3-cyanobenzaldehyde and
  • the title compound was prepared from ethyl acetoacetate, 2-bromo-3-cyanobenzaldehyde and 3-aminopyrazole in the same manner as in Example 58. MP:230°C.
  • Example 70 4- (2, 1, 3-Benzoxadiazol-4-yl) -5-cyano-4, 7-dihydro-6- (pyrrolidin-2-yl) -2ff-pyrazolo [3, 4-b]pyridine
  • the title compound was prepared from 4- (2,1,3- benzoxadiazol-4-yl) -6- (1-t-butoxycarbonylpyrrolidin-2-yl) -
  • the title compound was prepared from ethyl 1-t-butoxy- carbonylpiperidine-4-carboxylate, 2, 3- (methylenedioxy) - benzaldehyde and 3-aminopyrazole in the same manner as in Example 1.
  • the title compound was prepared from 2, 1, 3-benzoxa- diazole-4-aldehyde, 3-aminopyrazole and methyl 2,2- dimethoxypropionate in the same manner as in Example 1.
  • methyl l-tert-butoxycarbonyl-3-pyrrolidinecarboxylate (2.6 g) in THF (10 mL) was added and the mixture was stirred for 10 hours and the reaction was quenched with water. The mixture was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (eluent: hexane-ethyl acetate (2:1)) to give l-(l-tert- butoxycarbonylpyrrolidin-3-yl) -2-cyanoethan-l-one (2.35 g) as a colorless oil.
  • the title compound was prepared from ethyl isonipecotate, 4-indancarboxaldehyde and 3-aminopyrazole in the same manner as in Example 1.
  • the title compound was prepared from methanesulfonyl- chloride, ethyl pipecolinate, 2, 1, 3-benzoxadiazole-4- aldehyde and 3-aminopyrazole in the same manner as in Example 25.
  • the title compound was prepared from 4- aminocyclohexanecarboxylic acid ethyl ester, 2-bromo-3- cyanobenzaldehyde and 3-aminopyrazole in the same manner as in Examples 15 and 2.
  • the title compound was prepared from ethyl nipecotate,
  • the title compound was prepared from ethyl nipecotate,
  • the title compound was prepared from ethyl nipecotate,
  • the reaction mixture was extracted with ethyl acetate, and the solvent was evaporated under reduced pressure to give colorless crystals (9.6 g) .
  • An Ammonia solution (3.0 g) and GDI (2.8 g) were added to the obtained colorless crystals (4.2 g) in DMF (20 mL) , and the mixture was stirred overnight.
  • the reaction mixture was extracted with ethyl acetate, and the solvent was evaporated under reduced pressure to give an oil.
  • the residue in N,N- dimethylacetamide dimethyl acetal (30 mL) solution was heated for 2 hours, and the solvent was evaporated under reduced pressure.
  • the title compound was prepared from 2, 2-dimethylglycine ethyl ester, 2-chlorobenzaldehyde and 3-aminopyrazole in the same manner as in Examples 15 and 2.
  • Example 73 Example 74 Example 75
  • Example 77 Example 78
  • Example 81 Example 82 Example 83 Example 84
  • Example 85 Example 86 Example 87 Example 88
  • Example 89 Example 90
  • Example 91 Example 91
  • Example 93 Example 94 Example 95
  • Example 96 Example 97
  • Example 98
  • Example 100 Example 101
  • Example 102 Example 102
  • Example 105 Example 106
  • Example 107
  • Example 108 Example 109 Example 110 Example 111
  • Example 112 Example 113
  • Example 114 Example 115
  • Example 116 Example 117 Example 118 Example 119
  • Example 120 Example 121 Example 122 Example 123
  • Example 124 Example 125
  • Example 126 Example 127
  • Example 128 Example 129 Example 130
  • Example 131 Example 131
  • Example 132 Example 133
  • Example 134 Example 135
  • Example 136 Example 137
  • Example 138 Example 139
  • Example 140 Example 141
  • Example 143 Example 143
  • Example 144 Example 145
  • Example 146 Example 147
  • Example 152 Example 153
  • Example 154 Example 155
  • Example 156 Example 157
  • Example 158 Example 159
  • Example 2 The compound of Example 1 (0.5 part), lactose (25 parts) , crystalline cellulose (35 parts) and corn starch (3 parts) were thoroughly mixed and kneaded well with a binder made of corn starch (2 parts) . The kneaded product was passed through a 16 mesh sieve, dried in an oven at 50°C and passed through a 24 mesh sieve. The kneaded powder thus obtained, corn starch (8 parts), crystalline cellulose (11 parts) and talc (9 parts) were thoroughly mixed and compression-punched to give tablets containing 0.5 mg of the active ingredient per tablet.
  • Formulation Example 2 Formulation Example 2
  • Example 1 The compound of Example 1(1.0 mg) and sodium chloride (9.0 mg) were dissolved in water for injection, and the solution was filtered to remove pyrogen. The filtrate was transferred into an ampoule under sterile conditions. After sterilization, the ampoule was weld-sealed to • give injection containing 1.0 mg of the active ingredient.
  • glycogen synthase kinase-3 beta (GSK-3 ⁇ ) were evaluated and confirmed as follows.
  • the compounds of the present invention showed the IC 5 o values of 1 to 1000 nmol/L.
  • the IC50 values of the compounds are shown in the following Table 1.
  • CREB Phosphopeptide is Lys-Arg-Arg-Glu-Ile-Leu-Ser- Arg-Arg-Pro-Ser ( P) -Tyr-Arg .
  • Hippocampal neurons were obtained from rat embryos on the 18th day after conception. After culturing the hippocampal neurons for 7 days, the neurons were treated with amyloid ⁇ (25-35) (20 ⁇ mol/L) and a test compound (GSK-3 ⁇ inhibitor) , and the culture was continued for 3 hours, whereby phosphorylation of Tau protein was induced. After the completion of culture, the level of phosphorylation of Tau protein was determined by EIA method using phosphorylated Tau-recognizing antibody
  • Hippocampal neurons were obtained from rat embryos on the 18th day after conception. After culturing the hippocampal neurons for 7 days, the neurons were treated with amyloid ⁇ (25-35) (20 ⁇ mol/L) and a test compound (GSK-3 ⁇ inhibitor) , and the culture was continued for 24 hours, whereby cytotoxicity (decreased activity of intracellular dehydrogenases) was induced. After the completion of culture, activity of intracellular dehydrogenases was determined, and the effect of the GSK-3 ⁇ inhibitor on the amyloid ⁇ -induced cytotoxicity was evaluated.
  • a test compound (GSK-3 ⁇ inhibitor) was intraperitoneally administered to gerbils, and 30 minutes later, brain ischemia was created by shutting off (for 4 minutes) all carotid arteries, whereby phosphorylation of Tau protein in the brain was induced.
  • the hippocampus was obtained from the gerbil brain, and the level of phosphorylation of Tau protein was determined by Western blot using phosphorylated Tau-recognizing antibody (phosphorylated site by GSK-3 ⁇ ) , based on which the GSK-3 ⁇ -inhibitory effect of the GSK-3 ⁇ inhibitor in the gerbil brain was evaluated.
  • the compounds of the present invention show a selective and strong inhibitory action on glycogen synthase kinase-3 beta (GSK-3 ⁇ ) , and are useful as medicaments for prevention and/or treatment of diabetes, diabetic complications, neurodegenerative diseases (Alzheimer's disease, ischemic cerebrovascular disorders, Down's syndrome, cerebral ischemia due to cerebral amyloid angiopathy, progressive supranuclear paralysis, subacute sclerosing panencephalitic Parkinsonism, postencephalitic Parkinsonism, boxer's encephalopathy, Parkinsonism dementia complex of Guam, Lewy body disease, Pick's disease, corticobasal degeneration, frontotemporal dementia, AIDS encephalopathy, Huntington' s disease, manic-depressive psychosis and the like) , alopecia, breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and several virus-induced tumors, or as immunopotentiators,

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés de dihydropyrazolopyridine de formule (I). Dans cette formule, chaque symbole est comme défini dans la description. L'invention concerne des formes optiquement actives de ces composés et des sels pharmaceutiquement acceptables desdits composés, ainsi que des hydrates de ceux-ci. Les composés de l'invention présentent une forte activité inhibitrice sélective sur la glycogène synthase kinase 3 bêta (GSK-3β), et sont utiles en tant que médicaments pour la prévention et/ou pour le traitement des diabètes, de complications diabétiques et de maladies neurodégénératives, ou en tant qu'immunopotentiateurs.
EP03784497A 2002-08-07 2003-08-01 Composes de dihydropyrazolopyridine Withdrawn EP1537106A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002230581 2002-08-07
JP2002230581 2002-08-07
PCT/JP2003/009787 WO2004014910A1 (fr) 2002-08-07 2003-08-01 Composes de dihydropyrazolopyridine

Publications (1)

Publication Number Publication Date
EP1537106A1 true EP1537106A1 (fr) 2005-06-08

Family

ID=31711689

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03784497A Withdrawn EP1537106A1 (fr) 2002-08-07 2003-08-01 Composes de dihydropyrazolopyridine

Country Status (14)

Country Link
EP (1) EP1537106A1 (fr)
JP (1) JP2005534713A (fr)
KR (1) KR20050069977A (fr)
CN (1) CN1675209A (fr)
AR (1) AR040961A1 (fr)
AU (1) AU2003250539A1 (fr)
BR (1) BR0313262A (fr)
CA (1) CA2494785A1 (fr)
EA (1) EA200500322A1 (fr)
IL (1) IL166482A0 (fr)
MX (1) MXPA05001434A (fr)
NO (1) NO20051153L (fr)
WO (1) WO2004014910A1 (fr)
ZA (1) ZA200501842B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ564757A (en) * 2005-06-27 2009-12-24 Sanofi Aventis Pyrazolopyridine derivatives as inhibitors of beta-adrenergic receptor kinase 1
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
US7741350B1 (en) 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
EP2391627B1 (fr) 2009-01-28 2013-12-25 Cara Therapeutics, Inc. Hétérocycles pyrazolo bicycliques
RU2012111354A (ru) 2009-08-26 2013-10-10 Санофи Новые кристаллические гидраты фторгликозидов, содержащие их фармацевтические препараты и их использование
FR2951172B1 (fr) 2009-10-13 2014-09-26 Pf Medicament Derives pyrazolopyridines en tant qu'agent anticancereux
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012120058A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683703B1 (fr) 2011-03-08 2015-05-27 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
EP2683698B1 (fr) 2011-03-08 2017-10-04 Sanofi Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683704B1 (fr) 2011-03-08 2014-12-17 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
EP2683702B1 (fr) 2011-03-08 2014-12-24 Sanofi Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
AU2014250392B2 (en) * 2013-04-05 2018-03-01 Eisai R&D Management Co., Ltd. Salt of pyrazoloquinoline derivative, and crystal thereof
EP3081566B1 (fr) 2013-12-13 2018-03-07 Daiichi Sankyo Company, Limited Dérivé de 5-hydroxy-4-(trifluorométhyl)pyrazolopyridine
CN104140427A (zh) * 2014-07-05 2014-11-12 湖南华腾制药有限公司 一种四氢吡唑并[1,5-a]嘧啶的制备方法
SG10202113198TA (en) 2017-06-01 2021-12-30 Eisai R&D Man Co Ltd Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
US11311530B2 (en) 2017-06-01 2022-04-26 Eisai R&D Management Co., Ltd. Lewy body disease therapeutic agent containing pyrazoloquinoline derivative
KR102627790B1 (ko) 2017-06-01 2024-01-23 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체와 메만틴을 병용한 치매 치료제
AU2018276566A1 (en) 2017-06-01 2019-11-07 Eisai R&D Management Co., Ltd. Pharmaceutical composition comprising PDE9 inhibitor
CN111217754B (zh) * 2018-11-23 2023-04-07 兰州大学 一种5-氨基-4-氰基吡唑的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916140A (en) * 1988-09-28 1990-04-10 Merrell Dow Pharmaceuticals Inc. Antiepileptic pyrazolopyridines
AU4878601A (en) * 2000-04-20 2001-11-07 Mitsubishi Corporation Aromatic amide compounds
KR20030076650A (ko) * 2001-02-02 2003-09-26 미쯔비시 웰 파마 가부시키가이샤 디하이드로피라졸로피리딘 화합물 및 그의 약학적 용도

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004014910A1 *

Also Published As

Publication number Publication date
AR040961A1 (es) 2005-04-27
IL166482A0 (en) 2006-01-15
EA200500322A1 (ru) 2005-08-25
ZA200501842B (en) 2006-05-31
BR0313262A (pt) 2005-07-12
CN1675209A (zh) 2005-09-28
AU2003250539A1 (en) 2004-02-25
KR20050069977A (ko) 2005-07-05
NO20051153L (no) 2005-04-04
JP2005534713A (ja) 2005-11-17
MXPA05001434A (es) 2005-06-06
WO2004014910A1 (fr) 2004-02-19
CA2494785A1 (fr) 2004-02-19

Similar Documents

Publication Publication Date Title
WO2004014910A1 (fr) Composes de dihydropyrazolopyridine
AU2016304408B2 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors
EP2751102B1 (fr) Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit
CA2953177C (fr) Composes d'imidazo[1,2-a]pyridine substitue utiles pour le traitement de la douleur
KR20210014108A (ko) Parp7 억제제로서의 피리다지논
AU2017263361A1 (en) Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors
CA3005658A1 (fr) Modulateurs de ror-gamma
EA039783B1 (ru) ПРОИЗВОДНЫЕ ТИРОЗИНАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
CA2845798A1 (fr) Composes et compositions pouvant etre utilises en tant qu'inhibiteurs des kinases pdgfr
CA3071825A1 (fr) Compose heterocyclique
WO2015110999A1 (fr) Inhibiteurs de ezh2 et leurs utilisations
CA3095880A1 (fr) Derives de pyrazolo-triazine et/ou de pyrazolo-pyrimidine en tant qu'inhibiteurs selectifs de kinase dependante de la cycline
EP0307141B1 (fr) Oxazoles et thiazoles pour le traitement de la démence sénile
AU2018201317A1 (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of RORc2 and methods of use thereof
US6977262B2 (en) Dihydropyrazolopyridine compounds and pharmaceutical use thereof
JP2011518127A (ja) ヒスタミンｈ３受容体アンタゴニストとしてのテトラヒドロナフチリジンおよびそれらのアザ誘導体
WO2015049629A1 (fr) Composés d'imidazoquinoline à utiliser en tant qu'inhibiteurs de bromodomaine
JP2017510653A (ja) ＰＡＲＰ阻害剤としての４Ｈ‐ピラゾロ［１，５‐α］ベンゾイミダゾール化合物のアナログ
CA3104955A1 (fr) Derives de tyrosine amide utilises en tant qu'inhibiteurs de la rho-kinase
AU2012233246B2 (en) Novel furanone derivative
WO2019094552A1 (fr) Modulateurs d'enzymes de modification du méthyle, compositions et utilisations associées
WO2010052222A1 (fr) Dérivés (dihydro)naphthyridinone comme antagonistes du récepteur h3 de l’histamine
CA2983391C (fr) 4-aminopiperidine acylee comme inhibiteurs de serine palmitoyltransferase
CA3036114A1 (fr) Compose cyclique aromatique de pyrido a cinq elements, son procede de preparation et son utilisation
CN114591334B (zh) 二氢吡唑并嘧啶酮衍生物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050301

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

17Q First examination report despatched

Effective date: 20050622

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20060930